title: [Invasive squamous cell carcinoma of the bladder: report of 18 cases and review of literature].
abstract: OBJECTIVE
  This study was undertaken to determine the most effective treatment for improvement of the prognosis of patients with squamous cell carcinoma of the bladder (SCC).
  
  
  METHODS
  The subjects included 18 cases of invasive SCC (T2 or worse) we have experienced in the past 10 years. While clarifying the clinical patterns of these cases, the association between stage, therapy, and prognosis was studied. Of the cases of invasive SCC reported in Japan in the recent 20 years, 54 cases in which the stage, therapy, and prognosis were documented were selected, and the association between the therapy and outcome in each stage was studied.
  
  
  RESULTS
  In our series, 11 cases are alive without cancer for over 2 years. Of the above patients, 7 underwent cystectomy. Cancer death was experienced in 7 patients. Of these patients, 3 underwent cystectomy, and 6 were classified as stage III or higher. As far as our study of the cases reported in Japan is concerned, the prognosis of the cases having undergone TUR or partial resection of the bladder alone was poor. But, even if patients underwent cystectomy, most of the patients was cancer death in the cases whose cancer was stage III or higher. In the patients receiving some supportive therapy, 4 patients receiving radiation plus cisplatin-based chemotherapy were all alive without for over 2 years.
  
  
  CONCLUSIONS
  Total cystectomy is most appropriate as the type of operation for the cases of invasive SCC. But, the cases whose cancer was stage III or higher have high recurrence rate, and must be accompanied with some supportive therapy. We concluded that radiation plus cisplatin-based chemotherapy is a candidate of most effective supportive therapy to improve the prognosis of those patients in the supportive therapy.
authors.affiliation: Department of Urology, Jikei University School of Medicine.
authors.forename: Norihiro
authors.initials: N
authors.lastname: Hayashi
authors.forename: Koji
authors.initials: K
authors.lastname: Asano
authors.forename: Akira
authors.initials: A
authors.lastname: Furuta
authors.forename: Isao
authors.initials: I
authors.lastname: Ikemoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Kishimoto
authors.forename: Haruki
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Onishi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Oishi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery
chemical_list: D002945:Cisplatin